Netherlands-based Forbion Capital Partners has closed its third life science fund at €183 million, enabling it to step up its investment into companies developing new drugs and medical technologies primarily located in Europe. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
